Multi-omic Analysis of Human B-cell Activation Reveals a Key Lysosomal BCAT1 Role in mTOR Hyperactivation by B-cell receptor and TLR9
Benjamin Gewurz,Rui Guo,Matthew Lim,Hardik Shah,Joao Paulo,Yuchen Zhang,Haopeng Yang,Liang Wei Wang,Daniel Strebinger,Nicolas Smith,Meng Li,Merrin Leong,Michael Lutchenkov,Jin-Hua Liang,Zhixuan Li,Yin Wang,Rishi Puri,Ari Melnick,Michael Green,John Asara,Adonia Papathanassiu,Steven Gygi,Vamsi Mootha
DOI: https://doi.org/10.21203/rs.3.rs-4413958/v1
2024-05-30
Abstract:B-lymphocytes play major adaptive immune roles, producing antibody and driving T-cell responses. However, how immunometabolism networks support B-cell activation and differentiation in response to distinct receptor stimuli remains incompletely understood. To gain insights, we systematically investigated acute primary human B-cell transcriptional, translational and metabolomic responses to B-cell receptor (BCR), Toll-like receptor 9 (TLR9), CD40-ligand (CD40L), interleukin-4 (IL4) or combinations thereof. T-independent BCR/TLR9 co-stimulation, which drives malignant and autoimmune B-cell states, jointly induced PD-L1 plasma membrane expression, supported by NAD metabolism and oxidative phosphorylation. BCR/TLR9 also highly induced the transaminase BCAT1, which localized to lysosomal membranes to support branched chain amino acid synthesis and mTORC1 hyperactivation. BCAT1 inhibition blunted BCR/TLR9, but not CD40L/IL4-triggered B-cell proliferation, IL10 expression and BCR/TLR pathway-driven lymphoma xenograft outgrowth. These results provide a valuable resource, reveal receptor-mediated immunometabolism remodeling to support key B-cell phenotypes including PD-L1 checkpoint signaling, and identify BCAT1 as a novel B-cell therapeutic target.